Patients with dystrophic epidermolysis bullosa had positive phase 3 results with Vyjuvek treatment, Krystal Biotech announced in a press release.
Vyjuvek (investigational beremagene geperpavec) is a noninvasive, topical, redosable gene therapy.
The randomized, double-blind, intra-patient, placebo-controlled phase 3 GEM-3 trial enrolled 31 patients with dystrophic epidermolysis bullosa (dystrophic EB) whose wounds were randomly assigned to receive either weekly Vyjuvek or placebo.
Complete wound healing as assessed by investigators occurred in 67% of the wounds treated with Vyjuvek, compared with